Efficacy and safety of alirocumab in patients with hypercholesterolemia not adequately controlled with non-statin lipid-lowering therapy or the lowest strength of statin: ODYSSEY NIPPON study design and rationale

Efficacy and safety of alirocumab in patients with hypercholesterolemia not adequately controlled with non-statin lipid-lowering therapy or the lowest strength of statin: ODYSSEY NIPPON study design and rationale

Abstract Background Statins are generally well-tolerated and serious side effects are infrequent, but some patients experience adverse events and reduce their statin dose or discontinue treatment altogether. Alirocumab is a highly specific, fully human monoclonal antibody to proprotein convertase su...

Full description

Bibliographic Details
Main Authors: Tamio Teramoto, Akira Kondo, Arihiro Kiyosue, Mariko Harada-Shiba, Yasushi Ishigaki, Kimimasa Tobita, Yumiko Kawabata, Asuka Ozaki, Marie T. Baccara-Dinet, Masataka Sata
Format: Article
Language:English
Published: BMC 2017-06-01
Series:Lipids in Health and Disease
Subjects:
Alirocumab
Hypercholesterolemia
Statin
Statin intolerance
Cardiovascular risk
PCSK9 inhibitor
Online Access:http://link.springer.com/article/10.1186/s12944-017-0513-7

Internet

http://link.springer.com/article/10.1186/s12944-017-0513-7

Similar Items